drugset / Trial / NCT01020734

Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

NCT01020734

Phase 2 Completed 263 enrolled Asan Medical Center
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and methotrexate before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying how well donor stem cell transplant or bone marrow transplant works in treating patients with acute myeloid leukemia in remission.

Timeline

Start
2011-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Background ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) Protein / enzyme biologic
Background Busulfan Small molecule Intravenous
Background Cyclophosphamide Other / unclassified Intravenous
Background Cyclosporine Peptide Oral
Background Fludarabine Small molecule Intravenous
Background Methotrexate Small molecule Intravenous

Indications